MARSHALL WACE, LLP - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 65 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$583,669
-62.3%
33,954
-51.3%
0.00%
-66.7%
Q4 2022$1,549,080
+2022.0%
69,747
+2002.7%
0.00%
Q4 2021$73,000
-91.0%
3,317
-82.3%
0.00%
-100.0%
Q1 2021$814,000
+164.3%
18,760
+152.3%
0.00%
+100.0%
Q4 2020$308,0007,4360.00%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Octagon Capital Advisors LP 831,267$22,419,0005.52%
Aquilo Capital Management, LLC 1,099,944$29,665,0005.39%
BVF INC/IL 2,005,862$54,098,0002.11%
Casdin Capital, LLC 1,115,455$30,084,0000.75%
Soleus Capital Management, L.P. 120,900$3,261,0000.51%
Eagle Health Investments LP 57,090$1,540,0000.49%
Centiva Capital, LP 358,863$7,220,0000.45%
VIKING GLOBAL INVESTORS LP 3,937,914$106,206,0000.29%
ArrowMark Colorado Holdings LLC 1,003,447$27,063,0000.21%
Perceptive Advisors 375,256$10,121,0000.15%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders